阿哌沙班与华法林在肾功能不全患者中的结局比较
这项多中心回顾性病历审查纳入肌酐清除率(CrCl)<25 mL/min、新启用阿哌沙班或华法林至少45天的患者,比较6个月内血栓与出血结局。阿哌沙班组128例、华法林组733例,校正心房颤动与冠状动脉旁路移植后,阿哌沙班组血栓和出血事件风险更低(HR 0.47,95%CI 0.25-0.92)。
要点
- CrCl<25 mL/min患者中,阿哌沙班组血栓和出血复合风险低于华法林组(HR 0.47,95%CI 0.25-0.92)。
- 血栓发生率阿哌沙班组5.5% vs 华法林组10.3%(P=.08),出血发生率5.5% vs 10.9%(P=.06)。
- 两组出血与血栓事件严重程度无差异,阿哌沙班可能作为华法林的合理替代选择。
核心结论
- 在CrCl<25 mL/min患者中,校正心房颤动和冠状动脉旁路移植后,阿哌沙班组血栓和出血事件风险低于华法林组(HR 0.47,95%CI 0.25-0.92)。
- 阿哌沙班可能作为严重肾功能不全患者中华法林的合理替代选择。
研究设计与样本
- 多中心回顾性病历审查,纳入新启用阿哌沙班或华法林至少45天且CrCl<25 mL/min的患者。
- 阿哌沙班组128例,华法林组733例,评估启动抗凝后6个月内的血栓和出血结局。
- 主要结局为首次出血或血栓事件的时间,采用Cox比例风险模型控制潜在混杂因素。
主要发现
- 首次出血或血栓事件时间在阿哌沙班组与华法林组间有显著差异。
- 校正心房颤动和冠状动脉旁路移植后,阿哌沙班组血栓和出血事件风险低于华法林组(HR 0.47,95%CI 0.25-0.92)。
- 血栓时间阿哌沙班组83天 vs 华法林组54天(P=.648),血栓发生率5.5% vs 10.3%(P=.08)。
- 出血时间阿哌沙班组46天 vs 华法林组54天(P=.886),出血发生率5.5% vs 10.9%(P=.06)。
- 两组出血和血栓事件的严重程度无差异。
关键数值与推荐
- 纳入标准:新启用阿哌沙班或华法林至少45天,且CrCl<25 mL/min。
- 主要结局:首次出血或血栓事件的时间。
- 校正心房颤动和冠状动脉旁路移植后,阿哌沙班组血栓和出血事件风险HR 0.47(95%CI 0.25-0.92)。
临床怎么用
- 作者认为,在严重肾功能不全患者中,阿哌沙班可能作为华法林的合理替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Apixaban in patients with impaired renal function is supported by limited data. Landmark clinical trials evaluating apixaban in patients with atrial fibrillation and/or acute venous thromboembolism excluded patients with creatinine clearance (CrCl) <25 mL/min. This multicenter, retrospective chart review was conducted to evaluate the safety and effectiveness of apixaban compared with warfarin in patients with CrCl <25 mL/min. Included patients were newly initiated on apixaban or warfarin for at least 45 days with a CrCl <25 mL/min. Patients were evaluated for thrombosis and bleeding outcomes 6 months following initiation of anticoagulation. The primary outcome was the time to first bleeding or thrombosis event. A total of 128 patients met inclusion criteria in the apixaban group and 733 patients in the warfarin group. Time to first bleeding or thrombosis event was significantly different between the apixaban and warfarin groups. Cox proportional hazards model was conducted to control for potential confounding factors for the primary outcome. After controlling for atrial fibrillation and coronary artery bypass grafting, risk of thrombotic and bleeding events was lower in the apixaban group (hazard ratio, 0.47; 95% confidence interval, 0.25-0.92). There was not a statistical difference between time to thrombosis (83 days vs 54 days, P = .648), rate of thrombosis (5.5% vs 10.3%, P = .08), time to bleeding (46 days vs 54 days, P = .886), or rate of bleeding (5.5% vs 10.9%, P = .06). The severity of bleeding and thrombotic events was not different between groups. Apixaban may serve as a reasonable alternative compared with warfarin in patients with severe renal dysfunction.
引用
- Hanni C, Petrovitch E, Ali M, et al. Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. Blood Adv. 2020. PMID: 32463871. doi:10.1182/bloodadvances.2019000972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。